IRIS
DE TURSI, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.176
AS - Asia 3.755
EU - Europa 3.582
SA - Sud America 622
AF - Africa 80
Continente sconosciuto - Info sul continente non disponibili 13
OC - Oceania 5
Totale 14.233
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.034
SG - Singapore 1.769
CN - Cina 849
IT - Italia 683
IE - Irlanda 677
BR - Brasile 501
RU - Federazione Russa 455
SE - Svezia 436
VN - Vietnam 434
UA - Ucraina 271
DE - Germania 257
FR - Francia 234
GB - Regno Unito 231
TR - Turchia 189
IN - India 170
HK - Hong Kong 82
FI - Finlandia 80
BD - Bangladesh 71
CA - Canada 61
MX - Messico 51
PL - Polonia 47
BE - Belgio 46
JP - Giappone 42
AT - Austria 39
AR - Argentina 33
ZA - Sudafrica 30
IQ - Iraq 28
NL - Olanda 27
ES - Italia 23
CO - Colombia 21
CZ - Repubblica Ceca 20
EC - Ecuador 18
PK - Pakistan 17
ID - Indonesia 14
EG - Egitto 13
PY - Paraguay 13
UZ - Uzbekistan 13
EU - Europa 11
MA - Marocco 11
VE - Venezuela 11
JM - Giamaica 10
LT - Lituania 10
CL - Cile 8
JO - Giordania 8
MY - Malesia 8
PT - Portogallo 8
RO - Romania 8
UY - Uruguay 8
KE - Kenya 7
PH - Filippine 7
SA - Arabia Saudita 7
AE - Emirati Arabi Uniti 6
CH - Svizzera 6
PE - Perù 6
AL - Albania 5
GR - Grecia 5
KR - Corea 5
TN - Tunisia 5
AU - Australia 4
GT - Guatemala 4
LB - Libano 4
NI - Nicaragua 4
NP - Nepal 4
AZ - Azerbaigian 3
BO - Bolivia 3
DZ - Algeria 3
ET - Etiopia 3
GE - Georgia 3
IL - Israele 3
OM - Oman 3
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
CM - Camerun 2
CR - Costa Rica 2
HN - Honduras 2
IR - Iran 2
MM - Myanmar 2
MN - Mongolia 2
RS - Serbia 2
SN - Senegal 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GD - Grenada 1
HU - Ungheria 1
KW - Kuwait 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
Totale 14.225
Salva come PNG Salva come JPEG
Città #
Singapore 1.342
Chandler 877
Dublin 653
San Jose 633
Ashburn 457
Jacksonville 447
Dallas 274
Princeton 262
Beijing 249
Los Angeles 176
Ho Chi Minh City 132
The Dalles 131
Council Bluffs 128
Santa Clara 126
Nanjing 125
Chieti 119
Izmir 112
Dearborn 105
Wilmington 105
Southend 104
New York 102
Altamura 100
Hanoi 96
Ann Arbor 89
Pescara 77
Hong Kong 75
Munich 74
Boardman 57
Cambridge 55
Buffalo 54
Moscow 51
Redondo Beach 50
Dong Ket 47
São Paulo 45
Brussels 44
Washington 41
Frankfurt am Main 38
Tokyo 38
Menlo Park 36
Warsaw 34
Orem 33
Rome 33
Tongling 32
Nanchang 30
Houston 29
Montreal 27
Milan 25
Helsinki 24
London 24
Shenyang 24
Boston 23
Denver 23
Johannesburg 23
Nuremberg 23
Atlanta 22
Chicago 22
Norwalk 22
Da Nang 21
Rio de Janeiro 21
St Louis 21
Vienna 21
Amsterdam 20
Hefei 20
Mexico City 20
Brooklyn 19
Falls Church 19
Hebei 19
Phoenix 19
Woodbridge 19
Kunming 18
Seattle 18
Tianjin 17
Chennai 16
Stockholm 16
Haiphong 15
San Francisco 14
Ancona 13
Baghdad 13
Hangzhou 13
Jiaxing 13
Poplar 13
Turku 13
Hyderabad 12
Toronto 12
Brno 11
Charlotte 11
Dhaka 11
New Delhi 11
Porto Alegre 11
Cairo 10
Edinburgh 10
Guayaquil 10
Manchester 10
Miami 10
Pune 10
Tashkent 10
Belo Horizonte 9
Campinas 9
Kingston 9
Redwood City 9
Totale 8.815
Salva come PNG Salva come JPEG
Nome #
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 193
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 180
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 178
A multicenter phase II study of Epirubicin (E) with low-dose Herceptin (LD-H) as a first line treatment in HER-2 overexpressing metastatic breast cancer (MBC): Preliminary Results 170
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 167
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 167
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 167
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 159
ABIRATERONE ACETATE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHEMOTHERAPY-NAIVE PATIENTS: AN ITALIAN MULTICENTER 'REAL-LIFE' 1-YEAR STUDY 157
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 156
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 156
Epidermal Growth Factor Immunotherapy: Exploring the Effects of NB-UVB Exposure 156
Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer 153
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction 152
High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study 149
PERITONECTOMIA ED HIPEC NEL TRATTAMENTO DELLA CARCINOSI PERITONEALE: RISULTATI PRELIMINARI DOPO UN ANNO DI ESPERIENZA 149
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 149
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 147
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 144
New Targets for Therapy in Pancreatic Cancer 144
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 143
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 140
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 139
PO-1074 Radiotherapy and immuno-check point inhibitors for brain metastases. A mono-institutional analysis 138
Cytokine Levels and UVr Sensitivity in HaCaT Cells and Cetuximab Treated Patients. 134
Speed rate (SR) as a new dynamic index of melanoma behavior 134
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 133
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 132
Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer 131
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 128
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 128
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study 128
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 127
Arterial Thrombosis in ambulatory cancer patients treated with chemotherapy. 127
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 127
Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical Response to Tyrosine Kinase Inhibitor 126
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 125
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 124
Principali effetti collaterali delle terapie mediche 122
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: A new algorithm for patient selection and personalized treatment 122
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 121
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study 121
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 121
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression 120
A real-life multicenter, retrospective analysis of Abiraterone Acetate (AA) in 340 metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy, updated results 119
A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer 118
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A “snapshot” from clinical practice 118
Alectinib induced regression of renal and hepatic cysts caused by crizotinib 118
A real -life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second -line therapy 116
Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy 115
Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study 115
Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts 115
Enzalutamide in patients with castration-refractory prostate cancer: Retrospective, multicenter, real life study 115
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study 114
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients 113
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 112
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 112
Persistence and adherence to androgen deprivation therapy in men with prostate cancer: an administrative database study 112
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy(HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis ofovarian origin 111
Rivaroxaban for cancer-associated cardiac thrombosis 111
Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: A systematic review 110
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial 110
Phenotypic and proteomic analysis identifies hallmarks of blood circulating extracellular vesicles in NSCLC responders to immune checkpoint inhibitors 110
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 109
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 109
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 108
Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study 108
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study 106
Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study 106
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score 104
Low Phosphatidylserine+ Cells Within the CD34+/CD45dim/CD117(c-kit)+ Subpopulation Are Associated with Poor Outcomes in Metastatic Colorectal Cancer 103
Real world treatment practice in patients with advanced melanoma in the nivolumab era: five novel Italian case reports and a literature review 100
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 100
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results 98
Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients 98
Pretreatment neutrophil-lymphocyte ratio (NLR) predicted overall survival (OS) for metastatic melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) patients who received monotherapy with immune checkpoint inhibitor as ipilimumab, nivolumab and pembrolizumab 98
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 97
Cabazitaxel after Docetaxel in patients with metastatic, castration-resistant, prostate cancer (mCRPC): A prospective, observational study about toxicity profile and quality of life. 95
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 94
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 94
Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. 93
F05Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 93
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study 93
A multicenter phase II study of epirubicin (E) with low-dose herceptin (LD-H) as a first-line treatment in HER2 overexpressing metastatic breast cancer (MBC) 93
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A dose-finding study 92
PO-06 Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 92
P1.09 Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation in NSCLC 91
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 91
Axitinib after Sunitinib in metastatic renal cancer: Preliminary results from Italian "Real-World" SAX Study 90
null 90
Epirubicin plus low-dose trastuzumab in HER2 positivemetastatic breast cancer 89
Treatment and outcome (s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC) 89
Relationship and predictive role of the dual expression of FGFR and IL-8 in metastatic renal cell carcinoma treated with targeted agents 88
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice 88
Poor risk metastatic renal cell carcinoma (mRCC) patients are not a homogeneous group: a new stratificating model in the era of targeted therapy. 87
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. 87
Enzalutamide in real life: Results from a retrospective, multicenter, italian study 87
Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS) 87
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer 86
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: An insight from clinical practice 86
Totale 11.967
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.332
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.332
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022803 19 28 14 193 75 26 20 43 51 20 68 246
2022/20232.328 205 323 188 257 166 411 115 216 273 23 103 48
2023/20241.042 63 32 79 34 67 394 177 43 25 35 10 83
2024/20252.335 133 454 303 68 56 125 120 126 256 140 290 264
2025/20265.359 409 202 564 661 544 331 879 300 574 494 292 109
2026/202763 63 0 0 0 0 0 0 0 0 0 0 0
Totale 14.977